Recent summary of changes to the LAM
The tables below show a summary of changes to the list of approved medicines (LAM) since it was last published. The LAM is published monthly or more frequently if required.
Additions
Methoxsalen injection 100 microgram/5mL (SAS) |
Ryzodeg 70/30 Flextouch (insulin degludec + insulin aspart) - injection - 70 units/mL + 30 units/mL, 3 mL pen device |
Ryzodeg 70/30 Penfill (insulin degludec + insulin aspart) - injection - 70 units/mL + 30 units/mL, 3 mL cartridges |
Trabectedin injection 1mg |
Amendments
Buprenorphine + naloxone sublingual film (2 mg + 500 microgram, 8 mg + 2 mg) |
Buprenorphine sublingual tablet (2 mg, 8 mg, 400 microgram) |
Buvidal Monthly® (buprenorphine) modified release injection (64mg/0.18 mL, 96 mg/0.27 mL, 128 mg/0.36 mL, 160 mg/0.45 mL) |
Buvidal Weekly (buprenorphine) modified release injection (8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, 32 mg/0.64 mL) |
Dexmedetomidine Injection 200 microgram/2 mL |
Goserelin Implant 10.8mg |
Levamisole tablet 50mg (SAS) |
Levosimendan injection 2.5 mg/mL (SAS) |
Methadone syrup and oral solution not containing sorbitol, sugar, preservatives or alcohol - 5 mg/mL (200mL, 1L) |
Renflexis (infliximab) powder for injection 100mg |
Sublocade (buprenorphine) modified release injection (100 mg/0.5 mL, 300 mg/1.5 mL) |
Deletions
Diazepam enema 5 mg in 5 mL |
Efavirenz tablet 200mg, 600mg |
Podophyllotoxin cream 0.15%, 5g |
Last updated: 4 September 2023